Complete enrollment into Cohort 2 for cervical cancer trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Jan 2021
- Due
- 31 Dec 2021
- Delivered
- January 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Cervical : Complete enrollment into Cohort 2”
What we found
Evidence strength A What the grades mean
The company announced in January 2021 that enrollment for Cohort 2 of the C-145-04 cervical cancer trial was complete, meeting the 2021 deadline.
-
A Iovance Biotherapeutics, Inc. 10-K filed 2022-02-24
“In January 2021, we announced that Cohort 2 of the C-145-04 trial had completed enrollment” ✓ confirmed on the page
Market reaction: the shares moved +7.6% against the S&P 500 over the three sessions around the disclosure (23 Feb 2022 to 28 Feb 2022). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment into Cohort 2
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Iovance Biotherapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IOVA-021225 · Corrections policy